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Abstract 
 
 
Introduction:   
In patients with Non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT), prophylactic cranial irradiation (PCI) is not standard practice.  
This study determined patient preferences for PCI with respect to survival benefit, reduction in brain metastases (BM) and acceptable toxicity.  
 
Methods:   
A Discrete Choice Experiment was completed pre- and post- treatment. Patients made 15 hypothetical choices between two alternative PCI treatments 
described by four attributes: amount of life gained, chance of BM, ability to care for oneself, and loss of memory. Participants also chose between PCI and 
no PCI. 
 
Results:  
54 and 46 surveys were completed pre- and post-treatment. Pre-treatment the most important attributes were: a survival benefit >6 months, of 3 - 6 
months, avoiding severe problems with memory and self-care, avoiding quite a bit of difficulty with memory and maximally reducing BM recurrence. Post-
treatment, BM reduction became more important.  90% of patients would accept PCI for a survival benefit >6 months, with a maximal reduction in BM even 
if severe memory/self-care problems occurred.  With a 10% reduction in BM and mild problems with memory and self-care 70% of patients pre- (90% post-
treatment) would accept PCI for a survival benefit of 1-3 months, and 52% pre- (78% post-treatment) for no survival benefit.  
 
Conclusion:   
Improvement in survival is the most important attribute of PCI with patients willing to accept significant toxicity for maximum survival and less toxicity for 
less survival benefit. BM reduction became more important after treatment. The majority of patients would accept PCI for no survival benefit and a 
reduction in BM. 
  
INTRODUCTION 
 
Brain metastases (BM) develop in 22-55% of patients with locally advanced Non-small cell lung cancer (LA-NSCLC) treated with curative intent. [1,-4]  
Technological advances in tumour staging, radiation therapy (RT) planning and delivery, and the concurrent administration of chemotherapy with RT, has 
translated into improved local control and survival rates.[5,6]However, improvements in survival provide a longer time period for micro-metastatic disease to 
manifest and it is hypothesised that the incidence of BM will increase. 
 
In selected patients with limited- and extensive- stage small cell lung cancer (SCLC), the use of PCI is considered standard of care as PCI results in a 
decreased incidence of BM and an improvement in disease-free survival (DFS) and overall survival (OS). [7-9]In LA- NSCLC, PCI is not part of standard practice 
due to a lack of proven survival benefit and concerns regarding neurotoxicity. The Radiation Therapy Oncology Group (RTOG) 0214 study randomised 
patients with Stage III NSCLC treated with CRT to PCI or observation. PCI reduced the incidence of BM at 1 year (18% v 7.7%, p=0.004) but was not 
associated with an improvement in DFS or OS. However, the study was underpowered for a survival endpoint. [10]The use of PCI was associated with some 
adverse effects, namely a decline in delayed recall on the Hopkins Verbal Learning Test (HVLT). However, there were no differences observed between the 
study arms on Mini Mental Status Examination, Activities of Daily Living scale or quality of life (QOL) assessments. [11] 
 
The present study aimed to determine the preferences of patients with LA-NSCLC undergoing CRT with respect to PCI. Specifically, this study aimed to (i) 
estimate the relative importance of different characteristics potentially associated with PCI (survival gains, reduced chance of BM, reduction in ability to 
care for oneself and memory loss) for patients; (ii) estimate the impact of changes of these characteristics on the likelihood that patients would accept PCI, 
and (iii) explore whether undertaking CRT for lung cancer has an impact on patients preferences for PCI. 
 
 
METHODS 
 
A Discrete Choice Experiment (DCE) was used in a prospective cohort of patients with LA-NSCLC undergoing CRT at a single tertiary institution in 
Queensland, Australia, between June 2012 and December 2014. The DCE is a popular method for quantifying and evaluating patient preferences in 
healthcare. [12,13]    In a DCE, a medical intervention is described by its attributes (e.g. improvement in survival, or adverse effects).  A series of hypothetical 
choice sets is constructed in which the levels of these attributes change in a systematic way (according to an underlying experimental design). In each 
choice set, the participant is asked to perform a pairwise comparison of these hypothetical alternatives and choose their preferred alternative. Thus, 
participants exercise their preferences by making repeated trade-offs and choices across these hypothetical scenarios. 
 
Attributes and Attribute Levels 
 
The choice of the most relevant attributes and levels of PCI for LA-NSCLC was based on literature findings. [10, 11] The attributes chosen were: amount of life 
gained, chance of developing BM, ability to care for oneself and loss of memory.  Each attribute was described using four levels that were felt to represent 
potential outcomes from PCI. Each level was presented in a way that was felt to be meaningful to patients. For example, to assess the importance of 
developing BMs, patients were asked to choose between different “chances of cancer coming back in your brain” with the chances given as 20%; 4 in 20 
patients, (to approximate the 18% incidence of BM in the observation arm of RTOG 0214), 10%; 2 in 20 patients (to approximate the 7.7% incidence of BM 
in the treatment arm of RTOG 0214) with an intermediate level (15%; 3 in 20 patients) and a best case scenario level (5%; 1 in 20 patients). For amount of 
life gained, levels ranged from no extra life (reflecting ROTG 0214 results) to a hypothetical best case scenario of >6months of life gained,  with 
intermediate levels of 1-3 and 3-6 months of extra life. Similarly, to assess the importance of impact on memory and self-care, levels ranged from no 
problem or difficulty to severe problems or difficulties. The attributes and the associated levels are presented in Table 1. 
 
DCE choice set design and survey 
 
NGENE software (ChoiceMetrics, 2012) was used to combine the attributes and levels into 16 choice sets, using a D-optimal design approach. [14] This 
ensured a statistically efficient approach was used to capture the choice data. In each choice set the presented attribute levels were varied in order to 
capture the different trade-offs which individuals usually face with respect to their radiation treatment options. Participants were initially asked to choose 
between two alternative PCI treatments in each choice set. They were then asked to choose between their preferred PCI alternative and an opt- out 
alternative of no PCI. The opt- out alternative was described as providing no extra life, a 20% risk of BM, and no change in ability to take care of oneself or 
memory. Figure 1 presents an example choice situation. 
  
To assess whether the experience of undergoing conventional therapy impacted on participant choices, the DCE was undertaken two time points,: (1) just 
prior to commencement of CRT or during the first week of therapy; and (2) during the last week of therapy. In addition, the impact of patient 
sociodemographic factors and self-reported health status (obtained from the EQ-5D-5L instrument) on patient preferences was assessed. [15] The survey was 
pilot tested in an interview-based setting prior to data collection, to ensure the survey was understood by patients and had face validity. 
 
 
Sample and administration 
 
Ethical approval was obtained from the hospital Human Research Ethics Committee.  Patients were eligible if they were diagnosed with Stage III NSCLC and 
were to receive definitive CRT. Patients were identified at the weekly Lung Cancer Multi-disciplinary Meeting. Once consent had been obtained, the DCE 
was administered by trained nurses. The nurse presented each alternative to the participant in a face-to-face interview setting using a booklet, and 
recorded their choice.  Participants were informed that the scenarios were hypothetical. 
 
Data analysis 
 The choice data were analysed using mixed logit regression (MXL) models to indicate the relative importance of improvements in each attribute for 
treatment preference. [16] In a mixed logit model, the participant’s choices are related to the corresponding treatment attribute levels and a set of 
socioeconomic individual characteristics. Such an approach allows an estimate of the relative importance of each treatment attribute, in addition to the 
implied trade-offs between selected attributes, i.e. how much of one attribute a participant is willing to forgo in order to gain a fixed amount of another. It 
also allows an estimate of likely uptake for an intervention. 
 
The MXL model was specified as a linear function of the attribute levels. The constant term associated with treatment uptake was treated as random 
(following a normal distribution, using 1000 Halton draws for estimation) and dependent on other sociodemographic variables including the participant’s 
age, education level, employment status, marital status, and self-reported health status.  All attribute levels were effects coded, except for BM which was 
coded continuously. The opt out alternative of no PCI was specified with a fixed utility equal to that associated with no extra survival and a 20% chance of 
BM, as these were the levels used to describe the setting of “no PCI” in the DCE survey.  
 
The size of the coefficients in the models indicates the importance of improvements in different PCI treatment attributes. To estimate the relative 
importance of improvements in different attributes for participants and enable their comparison between the pre- and post-treatment models, the model 
coefficients were weighted for each model such that a 1% reduction in the chance of BM was given 1 point, and the other improvements were given a 
greater number of points in proportion to their relative importance for participants. The probability of uptake of PCI by participants, relative to not taking 
up PCI, was also estimated from the model based on the coefficients. This was estimated for selected scenarios representing a range of outcomes across 
the spectrum of attributes considered to be of particular relevance to clinical practice and the current evidence base for PCI treatment. 
 
RESULTS 
 
There were 54 and 46 surveys completed pre- and post-treatment, respectively.  The sample population appears representative of the LA-NSCLC patient 
population.  Participants had a mean age of 63.6 years (SD 10.1, range 39-82), and 74% were male. High-school was the highest educational level for 48% of 
patients.  The mean self-reported visual analogue score on the EQ-5D-5L was 74.3 out of 100 (SD 17.6, range 30 to 100). Participant characteristics are 
reported in Table 2. 
There were 807 choice observations available for analysis pre-treatment (54 participants x 15 choice sets less 3 missing responses) and 687 post-treatment 
(46 participants x 15 choice sets less 3 missing responses). One of the 16 choice sets was omitted in error from the post-treatment survey; therefore, only 
the 15 choice sets that were completed in both the pre- and post- surveys were included in the models. Estimation results from mixed logit models are 
reported in Table 3. Both models represented a reasonable fit for the choice data (pseudo-r squared 0.35-0.36), [17] and the estimated coefficients on the 
treatment attributes had the expected signs. For example, the coefficients for the ‘amount of extra life gained’ attribute levels were larger than the referent 
level of no extra life and statistically significant, broadly indicating that if the survival rate in one treatment alternative increases, then preference for that 
treatment alternative increases. The only counterintuitive result was for the attribute “taking care of oneself” for which the post-treatment model indicated 
a significant preference for “slight problems” over “no problems”. Overall, participants preferred a treatment alternative if it was associated with a longer 
survival, better ability to take care of oneself, lower loss of memory, and lower chance of occurrence of BM. 
 
The importance weights of the PCI attributes both before and after treatment, implied by the models are presented in Table 4 and Figure 2. Before 
treatment, an increase in survival of more than 6 months and of 3 to 6 months were the most important benefits (relative importance weights 61.2 and 
42.2 respectively), followed by avoiding severe problems with memory (39.4), avoiding severe problems with self-care (30.4), avoiding quite a bit of 
difficulty with memory (26.2), and a 15% reduction in risk of BM (15.0). After treatment, there were some differences in the rank order of importance with 
avoiding severe problems with self-care becoming more important than a 3-6 month gain in extra life, and avoiding severe problems with memory 
becoming less important. However, a reduction in the risk of BM became more important post-treatment, relative to improvements in the other attributes. 
That is, following treatment, participants appear to care more about the risk of cancer returning to their brain relative to the benefit of gains in other 
attributes, and are more willing to accept a reduced ability to care for oneself and increased memory loss, in order to achieve a reduced risk of BM. 
However, any comparison between the pre- and post-treatment survey is indicative only, due to the limited sample size. 
 
 
Participants chose to take up PCI in approximately two thirds of the raw choice sets (65.2% or 526/807 pre; 66.7% or 458/687 post; 65.9% or 984/1494 
overall). At the individual level, participants opted out of treatment by choosing “no PCI” for a mean of 5.2 (SD 5.2; median 3.0 IQR 0.75 to 10.0; range 0 to 
15) choice sets pre-treatment and 5.0 (SD 5.4; median 3.0, IQR 0.0 to 9.0; range 0 to 15) choice sets post-treatment. 
From the pre-treatment MXL model (Table 3), participants with a lower education level (highest level of education high-school) were on average more likely 
to consider PCI, all else equal, than those with a higher level of education (p<0.01). On the other hand, participants with better health levels (EQ-5D VAS 
score ≥75) were less likely to consider PCI compared to participants with lower levels of self-reported health; although this only reached significance at the 
10% level. None of the other sociodemographic characteristics (age, gender, employment status, marital status, carer status) were associated with the 
choice to take up PCI, either pre- or post-treatment; although this lack of association should be interpreted with caution, given the sample size. The 
estimated standard deviation corresponding to the constant term is large and statistically significant (at the 1% level) both pre- and post-treatment, 
indicating notable variation in tastes across individuals in their choice to accept PCI which is not explained by the included individual characteristics.  
 
The probability of uptake of PCI under a range of scenarios (in which the levels of the characteristics varied), relative to no PCI, both before and after CRT is 
presented in Tables 5 and 6. In the best case scenario of PCI providing >6 months extra life, a 15% reduction in chance of BM (from 20% to 5%) with no 
associated problems with self-care or memory, almost all participants (96%) would accept PCI. If PCI increased survival by > 6m and reduced BM risk by 15% 
(from 20% to 5%) but resulted in severe problems with self-care or memory loss, 63% of participants would accept PCI pre-treatment and 76% post-
treatment.  
 
In a scenario of PCI providing a small survival benefit (1-3m), a small reduction in BM (5% from 20% to 15%) and resulting in moderate problems with self-
care and quite a bit of difficulty with memory, 45% of patients pre-treatment and 71% of patients post treatment would accept PCI.  In a scenario of no 
survival benefit or reduction of BM risk with PCI, as long as patients were left with no adverse effects (defined as no problems with self-care or memory); 
over half of patient would accept PCI (57% before and 69% post conventional treatment). 
 
The factors that would prompt the vast majority of patients to take up PCI are presented in the last 4 columns of Table 5. Over 90% of participants would 
accept PCI if it gave at least a 10% reduction in absolute BM risk and 3 to 6 months survival benefit, as long as it was associated with no problems with self-
care or memory.  Over 80% would accept PCI if it gave at least a 10% reduction in the incidence of BM and 1-3m survival benefit, as long as there was no 
detrimental effect on self-care or memory. 
 
RTOG 0214 demonstrated that, at 1 year, PCI reduced the incidence of BM from 18% to 7.7% with no associated survival benefit and with a decline in 
memory (as measured by the HVLT).  We undertook hypothetical modelling using these findings and altering the survival benefit to investigate the uptake 
of PCI (Table 6).  Assuming PCI reduced the incidence of BMs by 10% (from 20% to 10%) and left patients with mild problems with self-care and memory 
over 90% of participants would accept PCI if it provided over 6 months survival benefit , 84% if survival benefit was 3 to 6 months (rising to 93% post-
treatment), 71% for 1 to 3 months survival benefit (rising to 90% post-treatment) and 52% (rising to 78% post-treatment) would accept PCI even if  there 
was no known survival benefit.   
 
 
DISCUSSION:   
 
Given that a significant proportion of patients with LA-NSCLC undergoing CRT develop BMs which negatively impacts neurocognitive function, QOL, and 
prognosis, there are compelling reasons why attempts to prevent BM have been investigated. [18]  Six randomised controlled trials have evaluated the role of 
PCI in LA-NSCLC, with five studies demonstrating a statistically significant reduction in the incidence of BM with PCI, but no survival advantage. [10, 19-23]    The 
most recent of these studies was underpowered for a survival endpoint. [10]  It is not clear whether patient refusal was the reason why target accrual was 
not met.  
 
The aims of this study were to estimate what factors were important from the patients’ perspective with regard to the use of PCI.  Specifically, we wished to 
address the relative importance of the different characteristics potentially associated with PCI (reduced chance of BM, impact on survival, reduction in 
ability to care for herself, memory impairment); the impact that changes in any of these characteristics would have on the patients’ preferences for PCI; and 
the impact of completing conventional treatment for LA-NSCLC on patients’ preferences. In this way, we wished to provide information which could inform 
decisions as to whether evaluating newer strategies, which aim to reduce the neurocognitive impact of whole brain radiotherapy, would be acceptable to 
patients.   
  
We found that participants would choose to undergo PCI in approximately two thirds of the hypothetical scenarios.  Participants with a higher educational 
level and, to a lesser extent, better health status were more likely not to choose PCI.  We hypothesise that patients with a higher level of educational 
achievement place more value on their neurocognitive abilities and therefore may be more concerned about the potential impact of PCI on their ability to 
function.  An alternative explanation that participants with a lower educational level did not understand the DCE concept cannot be discounted.  However, 
the survey was pilot tested in an interview-based setting prior to data collection, to ensure the survey was understood by patients.  In addition, the trained 
nurses who administered the DCE reported that a lack of understanding of the task was not an issue.  Similarly we hypothesise that patients with a better 
health status pre-treatment and who are desirous of returning to that level post-treatment, are more likely to be concerned about side effects that could 
have long term impact on their health status and ability to function. 
 
We found that improvement in survival is the most important potential characteristic of PCI for patients both pre and post-treatment and patients indicated 
they were willing to accept significant toxicity for maximum survival benefit.  If PCI resulted in a 6 month increase in survival and a 15% reduction in BM but 
resulted in severe problems with memory or ability to self-care, 63% of patients pre-treatment and 76% post-treatment would accept PCI.   The degree of 
toxicity deemed acceptable became less as survival benefit decreased, but a moderate amount of toxicity was still acceptable to a significant proportion of 
patients. For a survival benefit of 1-3 months, associated with a 5% reduction in BM, 45% of patients pre-treatment and 71% post-treatment would accept 
PCI, even if it was associate with moderate problems with self-care and quite a bit of difficulty with memory.    It could be hypothesised that the patients 
family or caregivers would have an impact on the trade-offs patients made between survival gain and potential impact on memory and self-care.  However, 
while we found that the patients marital or carer status did not influence their choice to accept PCI over no PCI, a result that should be interpreted with 
caution due to the small sample size, we did not examine the influence of family or carers on individual trade-offs.  This would be an interesting subject for 
further evaluation. 
 
 
While a potential survival gain was the most important characteristic of PCI, we found that patient’s preferences changed upon completion of treatment 
with a reduction in BM becoming more important relative to gains in other attributes.  That is, following treatment, participants appear to care more about 
the risk of cancer returning to their brain relative to the benefit of gains in other attributes, and are more willing to accept a reduced ability to care for 
oneself and increased memory loss, in order to achieve a reduced risk of BM.  The explanation for this preference change is uncertain.  We hypothesise that 
as patients approach the completion of their definitive therapy, they become more concerned about preventing disease recurrence in other parts of their 
body. 
 
 
When hypothetical scenarios were aligned with the findings of RTOG 0214 (ie an approximate 10% reduction in BM incidence) over 90% of patients would 
accept PCI for a potential survival benefit >6 months, 84% pre- and 93% post-treatment, for a potential survival benefit of 3-6 months, 71% pre- and 90% 
post-treatment for a potential survival benefit of 1-3 months, and 52% pre and 78% post for no survival benefit. These results confirm that while potential 
improvement in survival is most important, a reduction in BM incidence, particularly after completion of treatment is important for a significant proportion 
of patients. Furthermore, over 50% of patients indicated they would accept PCI if there were no improvement in survival or reduction in BM as long as there 
was no impact on memory or ability to self-care. This acceptance of treatment by a significant proportion of patients for minimal or no improvement in 
survival, has previously been documented in literature investigating the treatment preferences of women with breast cancer. [24, 25]  
 
 
Given that patients diagnosed with BMs have a median survival of 4 months, it seems reasonable that strategies attempting to prevent their occurrence 
and thereby improve survival continue to be pursued, particularly if such studies enrol patients deemed at high risk of developing BMs and employ 
techniques which have the potential to reduce the cognitive impact of WBRT.  [26] One such technique is hippocampal sparing WBRT (HS-WBRT).  HS-WBRT 
uses advanced RT technology to minimise the radiation dose delivered to the stem cell compartments involved in the neurogenesis of cells responsible for 
learning and memory functions. HS-WBRT was associated with a significant reduction in mean relative decline in HVLT delayed recall at 4 months in a 
randomised Phase II trial. [27] A prospective study of patients who examined multi-domains of neurocognitive function before and 4 months after HS-WBRT 
found neurocognitive function stabilised or improved.[28]   Multiple factors including the total RT dose, dose per fraction, concurrent chemotherapy and 
anticonvulsants, pre-existing cognitive impairment, and the effects of disease-progression have been proposed as impacting on cognitive function [26,29,30]  
Therefore the impact of HS-WBRT on avoiding neurocognitive decline needs to be assessed in randomised trials. There are currently two co-operative group 
Phase III trials addressing this question. (NRG-CC 003 and NRG-CC001). [31, 32] 
 
 Whether HS-WBRT could be safely employed as a strategy for delivering PCI will be dependent not only on the results of the above studies but also of 
studies investigating the risk and relapse of perihippocampal metastases in NSCLC.  Retrospective studies demonstrated the hippocampus to be a rare site 
of BM occurrence from all tumour histologies.[33,34]  A retrospective mapping study of 856 BMs in 100 patients (with the most common histology being 
NSCLC) found a 2.8% incidence of NSCLC BMs within the hippocampus, and an 8.3% incidence in a 5mm radius from the hippocampus.[35]  Modelling 
suggested a 0.2% absolute risk increase due to sub-therapeutic dosing of the hippocampus by HS-WBRT, leading the authors to conclude that HS-WBRT 
bears a low risk of undertreating patients.  [35] 
 
 
It is acknowledged that the results of this study need to be viewed in light of its limitations. Specifically, the small sample size means that any comparison 
between the pre- and post-treatment survey should be interpreted with caution.  In addition, it is acknowledged that cognitive decline affecting memory 
and self-care can occur as a consequence of both PCI and BM and therefore the choice between these attributes is not fully discrete.  Furthermore, it is 
acknowledged that a survival benefit has not been associated with PCI, and thus including potential survival gains as an attribute can be questioned.  
However, no survival benefit is included as one attribute level. Moreover, the aim of this study was to determine how much hypothetical improvement in 
survival patients would deem sufficient to accept any potential side effects of therapy. Despite these limitations to the authors’ knowledge, this is the first 
study which has tried to ascertain the preferences of patients who have been diagnosed with LA-NSCLC and who are undergoing CRT with respect to the 
role of PCI.  Furthermore, the use of a DCE methodology, although hypothetical, is widely accepted approach to eliciting patient preferences in healthcare, 
including radiation oncology [36,37] 
 
In conclusion, the use of PCI in unselected patients with LA-NSCLC undergoing curative therapy has resulted in a statistically significant reduction in the 
incidence of BMs but no proven survival advantage.  The results of this study show that, while from the patients’ perspective, improvement in survival is the 
most important potential attribute of PCI, and that the degree of acceptable toxicity is dependent on the amount of life gained, reduction in the incidence 
of BMs became more important, relative to other attributes after the completion of therapy.  Indeed, if PCI resulted in a 10% decrease in the incidence of 
BMs and no survival benefit (as occurred in RTOG 0214), the majority of patients would accept PCI.  The results of this study  therefore suggest that 
research protocols assessing the benefit of PCI in selected patients at high risk of developing BM and using PCI techniques with a potential for reducing 
cognitive impacts, would be acceptable to patients. 
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Figure 1: Example of a choice situation from the DCE (Pre-treatment Survey, Choice Situation 1) (Supplementary) 
 
 
Figure 2: Implied importance weights for improvement in PCI treatment attributes 
 
 
 
Table 1: Attributes and Levels for the DCE choice sets 
 
 
 
Table 2: Sample characteristics of participants, n=54  
 
 
Table 3: MXL Model Results, Pre and Post Treatment  (Supplementary) 
 
Table 4: Implied importance weights for improvement in PCI treatment attributes (Supplementary) 
 
 
Table 5: Estimate for probability of PCI uptake in selected hypothetical scenarios, pre and post treatment 
 
Table 6: Estimate for probability of PCI uptake in selected hypothetical scenarios, pre and post treatment (aligned with clinical evidence from RCT) 
 
 
 
 
 
